Scarica l'app Stockscreener
2.12
5.78%
-0.13
Pre-mercato:
2.15
0.03
+1.42%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TPST Giù?
Forum
Previsione
Frazionamento azionario
Tempest Therapeutics Inc Borsa (TPST) Ultime notizie
Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts - Bitget
Tempest Therapeutics names Andrew Fang head of business development - Investing.com
Tempest Therapeutics names Andrew Fang head of business development By Investing.com - Investing.com South Africa
Tempest brings in China dealmaker for Phase 3-ready cancer drug - Stock Titan
Tempest Therapeutics(TPST) Stock Options Chain | Quotes & News - Moomoo
Form S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments - ADVFN
Tempest Therapeutics (NASDAQ: TPST) registers 2.78M resale shares from private placement - Stock Titan
Tempest Therapeutics (NASDAQ: TPST) registers 8.27M shares for resale by sellers - Stock Titan
Buyout Rumor: What is Stran Company Incs revenue forecast2026 Technical Patterns & Weekly Breakout Stock Alerts - baoquankhu1.vn
New Strong Buy Stocks for April 10th - The Globe and Mail
[EFFECT] Tempest Therapeutics, Inc. SEC Filing - Stock Titan
TPST Forecast, Price Target & Analyst Ratings | TEMPEST THERAPEUTICS INC (NASDAQ:TPST) - ChartMill
Tempest Therapeutics, Inc. announced that it has received $1.999539 million in funding from Factor Bioscience Inc. and other investors - marketscreener.com
Tempest Therapeutics (TPST) grants 22,000 stock options to Corporate Controller - Stock Titan
Tempest Therapeutics (TPST) CFO receives 140,000 stock options at $1.64 - Stock Titan
Versant funds report lower Tempest Therapeutics (TPST) ownership levels - Stock Titan
Biopharmaceutical company Tempest Therapeutics Inc (TPST) recently filed a prospectus with the U.S. Securities and Exchange Commission, planning to issue up to approximately 2.8 million common shares through resale, including related warrants. - Bitget
According to a filing submitted to the US Securities and Exchange Commission (SEC), Tempest Therapeutics Inc. will not receive any proceeds from the sale of the company's shares by selling shareholders. - Bitget
Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Tempest Therapeutics (TPST) - The Globe and Mail
H.C. Wainwright Maintains Tempest Therapeutics(TPST.US) With Buy Rating, Maintains Target Price $11 - moomoo.com
TPST Q4'25 Earnings: EPS estimate is (0.62) USD - TradingView — Track All Markets
According to the latest filing disclosed by the SEC, existing shareholders of biopharmaceutical company Tempest Therapeutics Inc. plan to resell up to 8.27 million shares of the company's common stock. - Bitget
Scienture Holdings Inc (MEDS) Reports FY2025 Earnings - AlphaStreet
Tempest Reports Year End 2025 Financial Results and Provides Business Update - bitget.com
Tempest reports year end 2025 financial results and provides business update - marketscreener.com
Tempest Therapeutics, Inc. (TPST) Reports FY2025 Earnings - AlphaStreet
Tempest Therapeutics 2026 10-K: Pipeline Overview, CAR-T & Small Molecule Oncology Strategies, Key Partnerships, and Competitive Position - Minichart
Tempest Therapeutics 2025 Loss/Shr $6.33 >TPST - Moomoo
Tempest's new CEO arrives as six myeloma patients hit complete response - Stock Titan
Tempest Therapeutics 10-K: Net loss $26.3M, EPS $(6.33) - TradingView
Tempest Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Tempest Therapeutics (NASDAQ: TPST) advances dual CAR-T and liver cancer drug strategy - Stock Titan
Tempest Therapeutics (NASDAQ: TPST) details 2025 loss and CAR-T pipeline gains - Stock Titan
Tempest Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
TPST Should I Buy - Intellectia AI
Angel Matthew, CEO and president, buys Tempest Therapeutics shares for $500k - Investing.com Australia
Tempest Therapeutics Insider Bought Shares Worth $500,001, According to a Recent SEC Filing - Moomoo
Matthew Angel’s 37.4% Tempest (NASDAQ: TPST) stake tied to asset deal, private placement - Stock Titan
Factor Bioscience tied to Tempest (NASDAQ: TPST) CEO buys 231,482 shares - Stock Titan
TPST SEC FilingsTempest Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Downgrade Watch: Can Tempest Therapeutics Inc reach all time highs this yearRate Hike & Daily Profit Focused Screening - baoquankhu1.vn
Aug Macro: Will Tempest Therapeutics Inc stock recover after earningsMarket Trend Review & Real-Time Volume Trigger Notifications - baoquankhu1.vn
TPST Q4'25 Earnings: revenue estimate is 0 USD - TradingView — Track All Markets
Angel Matthew, CEO and president, buys Tempest Therapeutics shares for $500k By Investing.com - Investing.com South Africa
Tempest Therapeutics (TPST) Projected to Post Quarterly Earnings on Wednesday - Defense World
Tempest Therapeutics Announces $2 Million Private Placement and Securities Purchase Agreement with Institutional and Strategic Investors - Minichart
Tempest Therapeutics raises $2 million in private placement By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Tempest Therapeutics Announces Private Placement Financing Agreement - tipranks.com
Tempest Therapeutics raises $2 million in private placement - Investing.com
Tempest Therapeutics Raises $2.0 Million in Private Placement With Warrants Priced at $2.16 - TradingView
Tempest Therapeutics (Nasdaq: TPST) details $2.0 million private placement deal - Stock Titan
Tempest Therapeutics Announces Up To $6 Million Private Placement - Bitget
Tempest Therapeutics Inc expected to post a loss of 62 cents a shareEarnings Preview - TradingView
Technical Analysis: Is Tempest Therapeutics Inc exposed to political risk2026 Growth vs Value & Capital Protection Trade Alerts - baoquankhu1.vn
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):